Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is incurable with conventional therapies. Limited retrospective data have shown durable remissions after haematopoietic cell transplantation (HCT) [allogeneic (allo) or autologous (auto)]. We conducted a multicentre retrospective study in BPDCN patients treated with allo-HCT and auto-HCT at 8 centres in the United States and Canada. Primary endpoint was overall survival (OS). The population consisted of 45 consecutive patients who received an allo-HCT (n = 37) or an auto-HCT (n = 8) regardless of age, pre-transplant therapies, or remission status at transplantation. Allo-HCT recipients were younger (50 (14-74) vs. 67 (45-72) years, P = 0Á01) and had 1-year and 3-year OS of 68% [95% confidence interval (CI) = 49-81%] and 58% (95% CI = 38-75%), respectively. Allo-HCT in first complete remission (CR1) yielded superior 3-year OS (versus not in CR1) [74% (95% CI = 48-89%) vs. 0, P < 0Á0001]. Allo-HCT outcomes were not impacted by regimen intensity [3-year OS for myeloablative conditioning = 61% (95% CI = 28-83%) vs. reduced-intensity conditioning = 55% (95% CI = 28-76%)]. One-year OS for auto-HCT recipients was 11% (95% CI = 8-50%). These results demonstrate efficacy of allo-HCT in BPDCN, especially in patients in CR1. Pertaining to auto-HCT, our results suggest lack of efficacy against BPDCN, but this observation is limited by the small sample size. Larger prospective studies are needed to better define the role of HCT in BPDCN.
These data were presented in part at the annual meeting of the European Society for Blood and Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy derived from the precursors of plamacytoid dendritic cells, with a generally aggressive clinical course and high frequency of cutaneous and bone marrow (BM) involvement (Pagano et al, 2016) . The disease can also involve lymph nodes and other organs; clonal chromosomal aberrations, generally complex, have been reported in two-third of diagnosed cases Leroux et al, 2002; Tsagarakis, et al 2010) . Currently, there is no established standard induction chemotherapy regimen to treat BPDCN and the large majority of patients are prescribed regimens used for acute lymphoblastic (ALL) or acute myeloid (AML) leukaemia (Riaz et al, 2014; Pagano et al, 2016) . SL-401, a recombinant fusion protein that directly targets the interleukin 3 (IL3) receptor on the surface of BPDCN cells, has shown activity in this disease but responses appear to be short-lived (Frankel et al, 2000 (Frankel et al, , 2014 . Haematopoietic cell transplantation (HCT), particularly allogeneic HCT (allo-HCT), appears to yield durable remissions, especially if offered in first complete remission (CR1) (Kharfan-Dabaja et al, 2013) . Unfortunately, available data are limited to single-centre small case series or retrospective registry studies (Aoki et al, 2015; Dietrich et al, 2011; KharfanDabaja et al, 2013; Male et al, 2010; Reimer et al, 2003; Roos-Weil et al, 2013) . For instance, the European Society for Blood and Marrow Transplantation (EBMT) published outcomes of 34 BPDCN cases who received an allo-HCT, showing a 3-year disease-free survival (DFS) and overall survival (OS) of 33% and 41%, respectively (Roos-Weil et al, 2013) . Aoki et al (2015) reported 25 cases [allo-HCT = 14, autologous HCT (auto-HCT) = 11] from registry data of the Japanese Society for Haematopoietic Cell Transplantation, showing 4-year OS of 53% for allo-HCT and 82% for auto-HCT recipients, respectively. In their series, all auto-HCT recipients (n = 11, 100%) and 10 (71%) of 14 allografted patients were in CR1 at the time of the procedure (Aoki et al, 2015) .
We conducted a multicentre retrospective study that aimed to analyse outcomes of both allo-HCT and auto-HCT performed at 8 major transplant centres in the United States and Canada for patients with BPDCN.
Patients and Methods
A total of 45 patients with BPDCN received an allo-HCT (n = 37) or an auto-HCT (n = 8) between January 2000 and April 2017. Outcomes of 6 patients who received an allo-HCT have been previously published (Deotare et al, 2016) . Auto-HCTs were performed at only 2 of the 8 participating centres. The diagnosis of BPDCN was reviewed for accuracy and-confirmed at each one of the centres by an experienced haematopathologist, in line with the published 2008 World Health Organization classification (Swerdlow et al, 2008) . Data were analysed retrospectively. This study was approved by the designated institutional review board or ethics committee of each participating centre and was conducted in accordance with the declaration of Helsinki.
In the case of allo-HCT recipients, there were no restrictions in regards to age, remission status at the time of transplantation, donor source [human leucocyte antigenmatched-related (MRD), matched-unrelated (MUD), mismatched unrelated (MMUD), umbilical cord blood (UCB) or haploidentical donors], or cell source [BM, peripheral blood stem cells (PBSC) or UCB]. In the case of auto-HCT, there were no restrictions in regards to age, remission status at time of transplantation, and type of conditioning regimen [total-body irradiation (TBI)-based or chemotherapy-based].
For allo-HCT, acute graft-versus-host disease (GVHD) was graded according to 1994 consensus criteria (Przepiorka et al, 1995) . Chronic GVHD was graded using National Institutes of Health consensus development (Filipovich et al, 2005) .
Study objectives, definition of endpoints, and statistical methodology
The primary endpoint of the study was OS. Secondary endpoints (for both allo-HCT and auto-HCT) included: time to neutrophil or platelets engraftment, relapse/progression, progression-free survival (PFS), non-relapse mortality (NRM) and causes of death. Specifically for allo-HCT, we also evaluated cumulative incidence of acute GVHD (by day +100) and chronic GVHD (all grades or moderate/severe) by 1-year.
Time to neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count (ANC) of ≥0Á5 9 10 9 /l after post-transplant nadir. Time to platelet engraftment was defined as the first of 3 consecutive days with a platelet count of ≥20 9 10 9 /l or higher in the absence of platelets transfusion for 7 consecutive days. NRM was defined as time to death without relapse or progression. Relapse/progression was defined as recurrence or progression of the primary disease when compared to baseline remission status at the time of HCT. PFS was defined as the time from HCT to disease progression, relapse or death. OS was defined as time from HCT to death from any cause and censored at time of last follow-up. We summarized baseline characteristics (patient, disease or procedure) using descriptive statistics, such as median, standard deviation and range, for continuous measures; and frequencies and proportion for categorical measures. Probabilities of OS were calculated using the Kaplan-Meier estimate. Also, cumulative incidence of NRM was evaluated using a competing-risks model by Gray (1988) with relapse/ progression as a competing risk. This methodology was also used to measure cumulative incidence of relapse/progression, where NRM was a competing risk. Additionally, cumulative incidence of grade 2-4 acute GVHD (by day +100) and chronic GVHD (all grades and moderate/severe) by 1 year were estimated, accounting for death and relapse/progression as competing events.
Differences in survival curves when comparing reduced intensity conditioning (RIC) versus myeloablative conditioning (MAC) allo-HCT or by comparing allo-HCT performed in CR1 versus not in CR1 were assessed using Log-rank test. A two-sided P < 0Á05 was the defined cut-off for statistical significance. Univariate analyses for PFS and OS were performed by means of the Cox proportional hazards (PH) regression model. The final multivariate model was selected by allowing variables with P < 0Á1 to remain in the model and adjusting for patient's age, remission status at time of transplantation, regimen intensity, cell source and CD34 cell dose, even if the P-value exceeded 0Á1. Statistical analysis was performed using STATA (StataCorp LP, College Station, Texas, USA) and NCSS 11 (2016) (NCSS, LLC, Kaysville, Utah, USA).
Results
Patients who received an allo-HCT were relatively younger than those who received auto-HCT (median ages: 50 vs. 67 years, P = 0Á01) ( Table I) .
Allo-HCT
Thirty-seven patients [male = 29, 78%; median age, 50 (14-74) years] received an allo-HCT following a MAC (n = 20, 54%) or RIC (n = 17, 46%) regimen from a MRD (n = 16, 43%), MUD (n = 12, 32%), MMUD (n = 2, 5%), UCB (n = 4, 12%) or haploidentical (n = 3, 8%) donor. PBSC was the predominant cell source (n = 25, 68%). The large majority were allografted in CR1 (n = 28, 76%). These and other characteristics are summarized in Table I .
The median time from original diagnosis to allo-HCT was 7 (4-42) months. The median follow-up of surviving patients was 19 (1-136) months.
Engraftment kinetics, GVHD (acute and chronic), NRM and relapse/progression
The median time to neutrophil and platelets engraftment was 16 (11-30) days and 15 (7-45) days, respectively for all allo-HCT recipients. For MAC allo-HCT, median time to neutrophil and platelets engraftment was 16 (11-26) days and 14 (11-45) days, respectively. Similarly, for RIC allo-HCT, median time to neutrophil and platelets engraftment was 18 (11-30) days and 21 (7-45) days, respectively. The one (2Á7%) patient who experienced primary graft failure after a myeloablative MRD allo-HCT was in CR1, but had a low CD34 + cell count (1Á56 9 10 6 /kg recipient body weight). The median time to onset of acute GVHD was 35 (10-117) days. Cumulative incidence of 100-day grade 2-4 acute GVHD was 37% [95% confidence interval (CI) = 24-59%]. The cumulative incidence of chronic GVHD at 1 year was 61% (95% CI = 46-81%) for all grades and 28% (95% CI = 15-53%) for moderate/severe.
The cumulative incidence of NRM at 100 days, 6 months and 1 year was 6% (95% CI = 2-22%), 25% (95% CI = 13-45%) and 25% (95% CI = 13-45%), respectively.
Cumulative incidence of relapse/progression was 10% (95% CI = 3-29%) at both 1 and 3 years after transplantation.
PFS and OS
PFS. The 1-and 3-year PFS was 65% (95% CI = 45-76%) and 55% (95% CI = 35-72%), respectively. For patients who underwent an allo-HCT in CR1, the 1-and 3-year PFS was 85% (95% CI = 64-94%) and 69% (95% CI = 45-84%), respectively. On the other hand, 1-year PFS for patients allografted not in CR1 was 0. The mean PFS for patients For MAC allo-HCT, 1-and 3-year PFS was 66% (95% CI = 36-85%) and 55% (95% CI = 24-78%), respectively. For RIC allo-HCT, 1-year and 3-year PFS was 62% (95% CI = 34-81%) and 55% (95% CI = 28-76%), respectively. Regimen intensity did not affect PFS [MAC reference, Hazard ratio (HR) = 1Á23 (95% CI = 0Á41, 3Á66), P = 0Á72].
OS. OS at 1 and 3 years from allo-HCT was 68% (95% CI = 49-81%) and 58% (95% CI = 38-75%), respectively (Fig 1) . The median OS was not reached. The 1-and 3-year OS for patients who underwent allo-HCT in CR1 was 88% (95% CI = 66-96%) and 74% (95% CI = 48-89%), 
HCT-comorbidity index at time of HCT 0 15 (41%)
MAC regimens: busulfan (BU) plus fludarabine (FLU) = 10 (includes two cases with cladribine); cyclophosphamide (CY) + total body irradiation (TBI) = 6 (includes one case with FLU); etoposide + TBI = 3; BUCY = 1. RIC regimens: FLU+ melphalan = 7; FLU+200 Gy TBI+anti-thymocyte globulin = 3; FLU-BU+200 Gy TBI = 3; FLU-BU = 2; FLU-CY-TBI = 1; etoposide+TBI (adjusted) = 1. Allo-HCT, allogeneic haematopoietic cell transplantation; Auto-HCT, autologous haematopoietic cell transplantation; BEAM, carmustine, etoposide, cytarabine, melphalan; BM, bone marrow; CMV, cytomegalovirus; CNS, central nervous system; CR, complete remission; GVHD, graft-versus-host disease; HCT, haematopoietic cell transplantation; Hyper-CVAD, cyclophosphamide, vincristine, adriamycin, dexamethasone, methotrexate and cytarabine; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; MMUD, mismatched unrelated donor; MRD, HLA-matched-related donor; MTX, methotrexate; MUD, HLA-matched unrelated donor; PBSC, peripheral blood stem cells; PIF, primary induction failure; RIC, reduced intensity conditioning; UCB, umbilical cord blood. *Included: SL-401 = 3; cytarabine plus anthracycline = 2; high-dose cytarabine = 1, azacitidine = 1; Berlin-Frankfurt-Munster regimen = 1; CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) = 1; Fludarabine plus asparaginase = 1; methotrexate plus ciclosporin = 1; clinical trial = 1. †Include 4 cases of patients receiving post-transplant cyclophosphamide. ‡Alemtuzumab plus ciclosporin = 3; tacrolimus plus post-transplant cyclophosphamide = 1. §Excludes 4 cases of UCB and CD34 cell dose data missing in 1 allo-HCT case. ¶SL-401 = 3; CHOP = 1. respectively (Fig 2) . On the other hand, 1-year OS for patients allografted not in CR1 was 0 (Fig 2) . The mean OS for patients undergoing allo-HCT in CR1 was 29 (1-136) months compared to only 5 (1-13) months when not in CR1 (P < 0Á0001).
For MAC allo-HCT, 1-and 3-year OS was 74% (95% CI = 44-89%) and 61% (95% CI = 28-83%), respectively (Fig 2) . For RIC allo-HCT, 1-year and 3-year OS was 62% (95% CI = 34-81%) and 55% (95% CI = 28-76%), respectively (Fig 3) .
Causes of death in allo-HCT recipients:
Twelve of 37 patients died. Two died from relapse/progression and 10 from causes other than relapse (infection/sepsis = 6, GVHD causing bowel perforation = 1; renal failure = 1, secondary malignancy = 1, unknown = 1)
Univariate and multivariate analysis
In univariate analysis, recipient age, CD34 cell dose, regimen intensity, cell source, acute and chronic GVHD were not associated with PFS or OS (Table II) . On the other hand, receiving an allo-HCT in CR1 (versus not in CR1) was associated with a significant improvement in PFS and OS (Table II) .
In multivariate analysis, receiving an allo-HCT in CR1 (versus not in CR1) was the only variable associated with a significant improvement in PFS and OS (Table III) .
Auto-HCT
Eight patients [male = 5, 63%; median age 67 (45-72) years] received high-dose chemotherapy consisting of a combination of carmustine, etoposide, cytarabine and melphalan (BEAM) followed by auto-HCT. Five (63%) of 8 were in CR1 at the time of auto-HCT. These and other characteristics are summarized in Table I .
The median time from diagnosis to auto-HCT was 6 (3-25) months. The median follow-up for surviving patients (n = 3) was 6 (4-13) months.
Engraftment kinetics, NRM, and relapse/progression
The median time to neutrophil and platelets engraftment was 10 (9-11) days and 14 (10-42) days, respectively. Two (25%) patients (aged 66 and 72 years) died from cardiac-related events at 2 and 6 months after autografting. Three (38%) patients had evidence of relapse at a median of 4 (3-5) months; all 3 showed evidence of BM relapse, two of them had evidence of lymphadenopathy, one had skin involvement, and one had paratracheal involvement. Of note, 2 of the 3 patients who relapsed had received an auto-HCT in CR1 and the third was autografted in second complete remission. Time from relapse to death for these 3 patients was 1, 8 and 9 months, respectively.
Variables PFS OS
HR (95% CI) P-value HR (95% CI) P-value
Bold denotes statistical significance. 95% CI, 95% confidence interval; BM, bone marrow; CR1, first complete remission; GVHD, graft-versus-host disease; HCT, haematopoietic cell transplantation; HR, hazard ratio; MAC, myeloablative conditioning; OS, overall survival; PBSC, peripheral blood stem cells; PFS, progression-free survival; RIC, reduced intensity conditioning. 
Bold denotes statistical significance. 95% CI, 95% confidence interval; BM, bone marrow; CR1, first complete remission; HCT, haematopoietic cell transplantation; HR, hazard ratio; MAC, myeloablative conditioning; OS, overall survival; PBSC, peripheral blood stem cells; PFS, progression-free survival; RIC, reduced intensity conditioning. 
PFS and OS
The 1-year PFS and OS was 11% (95% CI = 8-50%) for both endpoints. The median PFS and OS was 12 months (95% CI = 5-19) for both endpoints.
Discussion
Allo-HCT is an effective treatment for BPDCN when performed in CR1, highlighting the importance of early referrals of these patients to transplant centres for prompt evaluation and assessment of eligibility. The relatively low incidence of relapse observed in our study, for patients allografted in CR1 (only 3 of 28 cases), suggests that a bona fide graft-versus-BPDCN effect may be responsible for providing long-term disease control. This translated into significantly improved PFS and OS. For instance, 3-year OS for patients allografted in CR1 was 74% whereas no patients were alive at 1 year from allo-HCT if they were not in CR1 at the time of the procedure (Fig 2) . This highlights an unmet need to develop more effective front-line therapies for this disease. One known intrinsic limitation of studies involving retrospective data collection and analysis is the inability to determine precisely the number of BPDCN patients who were referred for allo-HCT or auto-HCT but were never transplanted. In our analysis, the intensity of the allo-HCT conditioning (MAC versus RIC) did not appear to impact PFS and OS; however, we acknowledge that our analysis was not intentionally designed (and not statistically powered) a priori to address this particular question. Our results, however, are in contrast to those published by the EBMT, which showed a benefit of using MAC regimens, resulting in improved DFS [HR = 0Á21 (95% CI = 0Á07, 0Á58), P = 0Á003] and OS [HR = 0Á22 (95% CI = 0Á07, 0Á63), P = 0Á005] (Roos-Weil et al, 2013). One plausible explanation is that in our series a higher proportion of patients were transplanted in CR1 compared to the EBMT series (76% vs. 56%), suggesting a limited role for myeloablative regimens in this setting. Anecdotal data supports the role of donor lymphocyte infusions when BPDCN relapses after an allo-HCT (Steinberg et al, 2011) . Consistent with the EBMT findings (Roos-Weil et al, 2013), age, cell source and chronic GVHD did not affect OS in our series. The 3-year OS of 58% for all allo-HCT recipients in our series (Fig 1) is in line with results published by the Japanese study of 53% at 4 years postallografting (Aoki et al, 2015) .
Published data supporting auto-HCT is anecdotal at best (Aoki et al, 2015) . Aoki et al (2015) showed an encouraging 4-year OS of 82% in patients who received an auto-HCT in CR1. Our results are in sharp contrast with results reported by Aoki et al (2015) , showing a 1-year OS of only 11%. One possible explanation for this discrepancy is the fact that in our series only 5 of 8 (63%) patients were in CR1 at the time of autografting compared to all 11 (100%) cases in the Japanese study (Aoki et al, 2015) . Moreover, the median age of patients in our series is apparently higher when compared to the Japanese study (67 vs. 57 years) . This may partly explain why, in our study, 2 of 8 (25%) auto-HCT patients died from non-relapse causes compared to none in the Japanese study (Aoki et al, 2015) . Finally, 5 of the 8 (63%) autografted cases in our series had high HCT comorbidity scores (Sorror et al, 2005) of 3 or higher. Information about HCT comorbidity scores was not reported in the Japanese study.
While another major limitation of retrospective studies is to determine with absolute certainty the rationale for clinical decisions, it is plausible that autografted patients were deemed ineligible for an allo-HCT as a result of advanced age or associated comorbidities. This argument may be further supported by the fact that, in the allo-HCT group, 68% received more intense prior therapies, namely hyper-CVAD (cyclophosphamide, vincristine, adriamycin, dexamethasone, methotrexate and cytarabine) compared to only 50% in the auto-HCT. It is plausible that less frequent use of intense front-line therapies might partly explain the lower observed CR rates prior to auto-HCT, perhaps suggesting that intensity of induction therapy may influence post-transplant survival outcomes.
The results of our study demonstrate efficacy of allo-HCT in BPDCN resulting in long-term disease control in approximately 55% of cases. We also demonstrate that remission status is an independent prognostic factor in allo-HCT for BPDCN, with encouraging 3-year OS of 74% when the procedure is offered in CR1. New and more effective therapies are needed to optimize front-line treatment responses in patients with BPDCN. In a phase 1/2 study for advanced haematological malignancies, 7 of 9 (78%) evaluable BPDCN cases showed objective responses [CR = 5, partial response (PR) = 2] after a single course of SL-401, but the median duration of responses was only 5 months (Frankel et al, 2014) . This highlights the urgency of proceeding with an allo-HCT in those cases achieving CR after SL-401, considering the anticipated short duration of responses. Moreover, better post-allografting surveillance strategies, such as development of minimal residual disease assays for patients without evidence of dermatological, central nervous system or marrow morphological relapse, are needed. This would allow implementing treatment strategies, such as infusion of donor lymphocytes or other interventions, when the disease is detected albeit non-bulky, to aim at increasing the probability of inducing remission and, ultimately, improving survival.
Emerging exome sequencing data showing that approximately half of examined cases had mutations affecting either the DNA methylation or chromatin remodelling pathways provides a rationale for studying epigenetic therapies for BPDCN and including them as a pre-, peri-or post-allo-HCT for this disease (Menezes et al, 2014) .
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